Dr Reddy’s Laboratories ke shares mein 2% ki girish aayi hai. Yeh girish tab aayi jab Goldman Sachs ne stock ko downgrade kar diya aur Citigroup ne cautious stance le liya. Dono brokerages ne growth visibility limited hone aur pipeline concerns ko wajah bataya hai.
Goldman Sachs aur Citi ne kyun kiya cautious?
Goldman Sachs ne Dr Reddy’s ko downgrade kiya hai. Citi ne bhi cautious stance le liya hai. Brokerages ke mutabiq, company ke earnings potential lower hai. Generics pricing pressure ki wajah se earnings pe dabaav hai. Semaglutide mein bhi muted opportunities hain. Pehle is drug se kaafi optimism tha, lekin ab analysts ko zyada opportunity nahi dikh rahi.
Valuation aur downside risks
Analysts ka kehna hai ki valuation risks bhi hain. Stock ka valuation zyada hai aur growth visibility limited hai. Pipeline concerns bhi hain. In sab factors ki wajah se downside risks near term mein persist kar sakte hain. Pehle jo optimism tha, woh ab kam ho gaya hai.
Hamaari Baat: Dr Reddy’s ke liye kya signal hai?
Hamari nazar mein, Goldman Sachs aur Citi ka cautious stance ek clear signal hai ki Dr Reddy’s ke liye near term mein challenges hain. Generics pricing pressure aur semaglutide mein limited opportunities — yeh dono major concerns hain. Investors ko cautious rehna chahiye. Agar aap Dr Reddy’s mein invested hain, toh downside risks ko samajh lena important hai. Yeh stock short term mein pressure mein reh sakta hai.
Sources & References
- Dr Reddy’s shares fall 2% after Goldman Sachs downgrades, Citi turns cautious — Original Story
